AUISET specializes in Aggregation-induced Emission solutions, a technology particularly useful in detecting hormone and infertility, and is determined to bring more rapid tests to the market.
Current Status
AUISET has launched its first AIE product in 2020. We have generated HKD $21.2M revenue as of September 2022 and our total sales is expected to reach HKD $28M by the end of 2022. AUISET is primarily focused on AIE research of female hormones, inflammation and cardiac markers and pet diagnostics.
Problem or Opportunity
All traditional fluorescent tags suffer from the Aggregation Caused Quenching (ACQ) phenomenon and cannot proportionally reflect the concentration of marker of interest when the concentration is too high. Besides, most rapid tests in the market, like those with colloidal gold as signal label, have low specificity and cannot provide quantitative measurements to present an accurate result profile.
Solution (product or service)
Aggregation-induced emission (AIE) is an unusual photophysical phenomenon in which luminous efficiency increases as molecules aggregate. AIE – nanoparticles (AIE – NP) carry AIE materials with high stability and many technical advantages. They do not suffer from ACQ phenomenon and are available in different colors and size ranges. They also allow variable surface modifications and have a tunable emission range from visible to near-infrared wavelength. Hence, AIE – NP can be widely used in many biomedical fields to provide highly specific and quantitative results.
Business model
By tapping into the local IVD market through distributing COVID-19 Antigen Rapid Test Kits this year, AUISET has secured a solid financial foundation for supporting further R&D work in multiple biomedical areas and seeking future partnerships.
